1887

Abstract

The inhibitory effect of human immunodeficiency virus (HIV) proteinase inhibitors amprenavir and saquinavir and antifungal agents terbinafine, ketoconazole, amphotericin B and ciclopiroxolamine on aspartyl proteinases (Saps) secreted by was tested in an spectophotometric assay. As expected, both HIV proteinase inhibitors showed a significant inhibitory effect on Sap activity, which was comparable to that of the classical aspartyl proteinase inhibitor pepstatin A ( < 0.001). Antifungal drugs such as ketoconazole, terbinafine and amphotericin B had no, or only minor, inhibitory effects on proteolytic activity. In contrast, a significant reduction in Sap activity could be demonstrated during treatment with the antifungal agent ciclopiroxolamine ( < 0.001). These results point to a multiple effect of this antimycotic agent and might explain the reduced adherence of to human epithelial cells at subinhibitory doses.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.05048-0
2003-03-01
2024-10-03
Loading full text...

Full text loading...

/deliver/fulltext/jmm/52/3/247.html?itemId=/content/journal/jmm/10.1099/jmm.0.05048-0&mimeType=html&fmt=ahah

References

  1. Borg-von Zepelin M, Meyer I, Thomssen R, Würzner R, Sanglard D, Telenti A, Monod M. 1999; HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 113:747–751 [CrossRef]
    [Google Scholar]
  2. Braga P. C, Piatti G, Conti E, Vignali F. 1992; Effects of subinhibitory concentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells. Arzneimittelforschung 42:1368–1371
    [Google Scholar]
  3. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. J. 1999; In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 180:448–453 [CrossRef]
    [Google Scholar]
  4. De Bernardis F, Sullivan P. A, Cassone A. 2001; Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol 39:303–313 [CrossRef]
    [Google Scholar]
  5. Hube B, Naglik J. 2001; Candida albicans proteinases: resolving the mystery of a gene family. Microbiology 147:1997–2005
    [Google Scholar]
  6. Korting H. C, Schaller M, Eder G, Hamm G, Böhmer U, Hube B. 1999; Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on the in vitro activity of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother 43:2038–2042
    [Google Scholar]
  7. Ollert M. W, Söhnchen R, Korting H. C, Ollert U, Bräutigam S, Bräutigam W. 1993; Mechanisms of adherence of Candida albicans to cultured human epidermal keratinocytes. Infect Immun 61:4560–4568
    [Google Scholar]
  8. Schaller M, Korting H. C, Schäfer W, Bastert J, Chen W. C, Hube B. 1999; Secreted aspartyl proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis. Mol Microbiol 34:169–180 [CrossRef]
    [Google Scholar]
  9. Watts H. J, Cheah F. S, Hube B, Sanglard D, Gow N. A. 1998; Altered adherence in strains of Candida albicans harbouring null mutations in secreted aspartic proteinase genes. FEMS Microbiol Lett 159:129–135 [CrossRef]
    [Google Scholar]
  10. Wu T, Samaranayake L. P, Leung W. K, Sullivan P. A. 1999; Inhibition of growth and secreted aspartyl proteinase production in Candida albicans by lysozyme. J Med Microbiol 48:721–730 [CrossRef]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.05048-0
Loading
/content/journal/jmm/10.1099/jmm.0.05048-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error